Paper4875390
The use of combinations of antimicrobial drugs.
Jawetz E. Annu Rev Pharmacol, 1968. Cited by 118 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The use of combinations of antimicrobial drugs. Papers, record 4875390. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4875390
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Drug Synergism | Major topic |
| Infections | Major topic |
| Animals | |
| Drug Antagonism | |
| Drug Resistance, Microbial | |
| Humans | |
| Mutation |
Source PubMed
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 118 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,701,178 | Spectrum meets sustainability: green-validated novel simultaneous assays of antimicrobial fixed dose combination. | BMC Chem | 2026 | https://conductscience.org/library/papers/42701178 | PubMed |
| 37,770,760 | Systematic analysis of drug combinations against Gram-positive bacteria. | Nat Microbiol | 2023 | https://conductscience.org/library/papers/37770760 | PubMed |
| 27,531,995 | Comparison of the In vitro Activity of Five Antimicrobial Drugs against Staphylococcus pseudintermedius and Staphylococcus aureus Biofilms. | Front Microbiol | 2016 | https://conductscience.org/library/papers/27531995 | PubMed |
| 26,029,671 | Sertraline enhances the activity of antimicrobial agents against pathogens of clinical relevance. | J Biol Res (Thessalon) | 2015 | https://conductscience.org/library/papers/26029671 | PubMed |
| 24,040,081 | Combination of alpha-melanocyte stimulating hormone with conventional antibiotics against methicillin resistant Staphylococcus aureus. | PLoS One | 2013 | https://conductscience.org/library/papers/24040081 | PubMed |
| 14,982,754 | Combination antifungal therapy. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/14982754 | PubMed |
| 12,069,981 | Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12069981 | PubMed |
| 7,399,713 | Prediction and significance of synergy between antibiotics used for treatment for gram-negative sepsis. | Infection | 1980 | https://conductscience.org/library/papers/7399713 | PubMed |
| 7,041,815 | Bactericidal activity of trimethoprim alone and in combination with sulfamethoxazole on susceptible and resistant Escherichia coli K-12. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/7041815 | PubMed |
| 6,859,835 | In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6859835 | PubMed |
| 6,360,040 | Radiometric macrophage culture assay for rapid evaluation of antileprosy activity of rifampin. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6360040 | PubMed |
| 6,289,731 | Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6289731 | PubMed |
| 6,249,191 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2. | Antimicrob Agents Chemother | 1980 | https://conductscience.org/library/papers/6249191 | PubMed |
| 5,052,053 | Combinations of antimicrobials. | Calif Med | 1972 | https://conductscience.org/library/papers/5052053 | PubMed |
| 4,984,762 | In vitro susceptibility of Pseudomonas aeruginosa to carbenicillin and the combination of carbenicillin and gentamicin. | Appl Microbiol | 1969 | https://conductscience.org/library/papers/4984762 | PubMed |
| 4,881,984 | The clinician's approach to drug interactions. | Calif Med | 1968 | https://conductscience.org/library/papers/4881984 | PubMed |
| 4,790,933 | Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci. | Antimicrob Agents Chemother | 1973 | https://conductscience.org/library/papers/4790933 | PubMed |
| 4,596,743 | Clinical significance of in vitro synergism between antibiotics in gram-negative infections. | Antimicrob Agents Chemother | 1972 | https://conductscience.org/library/papers/4596743 | PubMed |
| 4,494,488 | Antibiotic susceptibility of oxacillin-resistant staphylococci. | Antimicrob Agents Chemother | 1972 | https://conductscience.org/library/papers/4494488 | PubMed |
| 4,330,314 | In vitro chemotherapeutic combinations against isoniazid-resistant Mycobacterium tuberculosis and Mycobacterium fortuitum. | Appl Microbiol | 1971 | https://conductscience.org/library/papers/4330314 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4875390
GET https://conductscience.org/api/papers/v1/4875390/cited_by?page=2